Constitutive reduction in the checkpoint inhibitor, CTLA-4, does not accelerate SLE in NZM 2328 mice.
William StohlNing YuSamantha A ChalmersChaim PuttermanChaim O JacobPublished in: Lupus science & medicine (2019)
Lifelong reduction in CTLA-4 expression in NZM mice neither accelerated nor aggravated SLE. Expansion in Treg cells may have played a protective role. Our observations raise the hope that long-term treatment of patients with SLE with an anti-CTLA-4 agent, should the need arise, would not adversely affect SLE disease activity.
Keyphrases
- disease activity
- systemic lupus erythematosus
- rheumatoid arthritis
- rheumatoid arthritis patients
- ankylosing spondylitis
- juvenile idiopathic arthritis
- high fat diet induced
- induced apoptosis
- poor prognosis
- dna damage
- cell cycle arrest
- cell cycle
- wild type
- cell proliferation
- type diabetes
- metabolic syndrome
- oxidative stress
- adipose tissue
- signaling pathway
- smoking cessation
- endoplasmic reticulum stress